Polypill Eligibility for Patients with Heart Failure With Reduced Ejection Fraction in South India: A Secondary Analysis of a Prospective, Interrupted Time Series Study

Aishwarya Vijay, Padinhare P Mohanan, Dimple Kondal, Abigail Baldridge, Divin Davies, Raji Devarajan, Govindan Unni, Jabir Abdullakutty, Syam Natesan, Johny Joseph, Pathiyil B Jayagopal, Stigi Joseph, Rajesh Gopinath, Dorairaj Prabhakaran, Mark D Huffman, Anubha Agarwal, Aishwarya Vijay, Padinhare P Mohanan, Dimple Kondal, Abigail Baldridge, Divin Davies, Raji Devarajan, Govindan Unni, Jabir Abdullakutty, Syam Natesan, Johny Joseph, Pathiyil B Jayagopal, Stigi Joseph, Rajesh Gopinath, Dorairaj Prabhakaran, Mark D Huffman, Anubha Agarwal

No abstract available

Keywords: India; guideline‐directed medical therapy; heart failure with reduced ejection fraction; polypill.

Conflict of interest statement

In the past 3 years, M.D.H. received funding from the World Heart Federation to serve as its senior program advisor for the Emerging Leaders program, which has been supported by Boehringer Ingelheim, Novartis, Bupa, and AstraZeneca. M.D.H. also received support from the American Heart Association, Verily, AstraZeneca, and American Medical Association for work unrelated to this research. The George Institute for Global Health’s wholly owned enterprise, George Health Enterprises, has received investment funds to develop fixed‐dose combination products containing aspirin, statin, and blood pressure lowering drugs. M.D.H. and A.A. plan to submit patents for heart failure polypills, including for heart failure with reduced ejection fraction. The remaining authors have no disclosures to report.

References

    1. Harikrishnan S, Jeemon P, Ganapathi S, Agarwal A, Viswanathan S, Sreedharan M, Vijayaraghavan G, Bahuleyan CG, Biju R, Nair T, et al. Five‐year mortality and readmission rates in patients with heart failure in India: results from the Trivandrum heart failure registry. Int J Cardiol. 2021;326:139–143. doi: 10.1016/j.ijcard.2020.10.012
    1. Agarwal A, Bahiru E, Yoo SGK, Berendsen MA, Harikrishnan S, Hernandez AF, Prabhakaran D, Huffman MD. Hospital‐based quality improvement interventions for patients with heart failure: a systematic review. Heart. 2019;105:431–438. doi: 10.1136/heartjnl-2018-314129
    1. Agarwal A, Yancy CW, Huffman MD. Improving care for heart failure with reduced ejection fraction—a potential polypill‐based strategy. JAMA. 2020;324:2259–2260. doi: 10.1001/jama.2020.21395
    1. Agarwal A, Mohanan PP, Kondal D, Baldridge A, Davies D, Devarajan R, Unni G, Abdullakutty J, Natesan S, Joseph J, et al. Effect of a quality improvement intervention for acute heart failure in south India: an interrupted time series study. Int J Cardiol. 2021;329:123–129. doi: 10.1016/j.ijcard.2020.12.048
    1. Bahiru E, de Cates AN, Farr MR, Jarvis MC, Palla M, Rees K, Ebrahim S, Huffman MD. Fixed‐dose combination therapy for the prevention of atherosclerotic cardiovascular diseases. Cochrane Database Syst Rev. 2017;3:CD009868. doi: 10.1002/14651858.CD009868.pub3

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa